<DOC>
	<DOC>NCT02514772</DOC>
	<brief_summary>The study objective is to identify potential safety risks of the transition from US-licensed Rituxan® or EU-approved MabThera® to GP2013 (proposed biosimilar product) as compared to continuous treatment with the originator product in terms of general safety and immunogenicity.</brief_summary>
	<brief_title>GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Diagnosis of RA according to ACR 2010 criteria Completed one full treatment course with either Rituxan® or MabThera® Eligible for a further treatment course with Rituxan® or MabThera® Currently treated with methotrexate RA functional status class IV (ACR 1991 revised criteria) Systemic manifestation of RA Positive serology for hepatitis B or hepatitis C infection Active systemic infection History of cancer Known severely immunocompromised state Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>